As of last check in afterhours trading, Jounce Therapeutics Inc. (JNCE) was up 5.01% to trade at $7.75. During the regular session on Wednesday, shares of Jounce stock closed at $7.38, down 2.25 percent.
On the day of trading, JNCE stock volumes were 0.72 million shares, a substantial increase over the 396.95K average daily volume over the past three months. Throughout the trading session, JNCE stock fluctuated between $7.315 and $7.75. The company is to host a virtual event this month, news that came to be raising the JNCE stock.
What is the purpose of that event?
With a biomarker-driven approach, Jounce is dedicated to transforming the treatment of cancer through immunotherapy therapies that enable the immune system to attack tumors and provide long-term benefits to patients. Multiple JNCE development programs are currently underway while also advancing a number of translational science assets based on its robust discovery engine.
Earlier today, Jounce announced it would host a virtual Research and Development Day.
- The event will be held by JNCE on Wednesday, June 23, 2021, at 10:00 a.m. – 12:00 p.m. ET.
- JNCE management and scientific team members will present, as well as key opinion leader and Jounce scientific founder Robert Schreiber, PhD, of The Washington University School of Medicine.
- Those who are interested can access the webcast of the R&D Day by visiting the Investors and Media section of Jounce’s website under “Events and Presentations.”
- A replay of the webcast will be available after the presentation for 30 days.
Other developments:
Jounce (JNCE) also announced this week that the US Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody. The rights to develop and commercialize JNCE’s that antibody belong exclusively to Gilead Sciences, Inc. (Nasdaq: GILD). JNCE will receive a $25.0 million milestone payment upon IND clearance.
